InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
glenn1919 PremiumMember
03/09/24 9:28 AM
profile icon
Triple nickle Free
01/10/24 7:35 AM
profile icon
TheFinalCD PremiumMember
12/06/23 7:13 AM
profile icon
81vette Free
12/05/23 10:24 PM
profile icon
Terpi Free
11/24/23 11:32 AM
profile icon
Zorro Free
11/13/23 2:57 PM
profile icon
TimeFades Free
11/13/23 11:21 AM
profile icon
alchemytrader Free
01/20/21 5:19 PM
profile icon
SteevoTrader Free
01/20/21 9:01 AM
profile icon
alchemytrader Free
01/19/21 11:50 PM
profile icon
SteevoTrader Free
01/19/21 8:57 PM
profile icon
ClayTrader Free
01/19/21 5:40 PM
profile icon
Marketwise Free
01/19/21 12:37 PM
profile icon
Docstemcell2020 Free
01/19/21 9:28 AM
profile icon
Serge521 Free
12/22/20 10:49 AM
profile icon
interloper Free
08/20/20 11:55 AM
profile icon
DanSanTrades Free
08/17/20 10:06 AM
profile icon
ClayTrader Free
07/20/20 5:33 PM
profile icon
ClayTrader Free
06/17/20 4:16 PM
profile icon
ClayTrader Free
01/10/20 3:58 PM
profile icon
beambe Free
01/10/20 10:36 AM
profile icon
XenaLives PremiumMember
12/26/19 8:05 AM
profile icon
jonny_red Free
10/31/19 8:39 AM
profile icon
ClayTrader Free
10/29/19 4:43 PM
profile icon
BottomBounce Free
10/29/19 3:06 PM
profile icon
jonny_red Free
10/28/19 10:34 AM
profile icon
VMB-1 Free
10/25/19 11:31 AM
profile icon
VMB-1 Free
10/25/19 9:57 AM
profile icon
dndodd Free
10/25/19 9:19 AM
profile icon
Neverland66 Free
10/25/19 8:46 AM
profile icon
toybaby Free
10/25/19 8:05 AM
profile icon
VMB-1 Free
10/24/19 6:45 PM
profile icon
ClayTrader Free
10/22/19 4:17 PM
profile icon
toybaby Free
10/17/19 7:32 AM
profile icon
AugustaFriends Free
10/16/19 8:40 AM
profile icon
stock1ace1 Free
10/16/19 8:22 AM
profile icon
ADVFN_bioking Terminated
10/15/19 5:40 PM
profile icon
toybaby Free
10/15/19 1:46 PM
profile icon
toybaby Free
10/15/19 8:29 AM
profile icon
stock1ace1 Free
10/15/19 8:06 AM

Aclaris Therapeutics Inc (ACRS) RSS Feed

Followers
15
Posters
51
Posts (Today)
0
Posts (Total)
326
Created
09/06/16
Type
Free
Moderators
Trading BRUTAL under Cash balance , super hot Rebound Play

Market Cap $43 M / Cash $115 M or untill end 2021 / 2 APPROVED Products / 1 Phase 3 trial (common warts) with results expected in Q4 2019 and many other phase 2 programs / because of their strategic change they wants to out-license all their Prodcuts which means HUGE upfront payments for the company (more infos below)= CHEAPEST Biotech you can get at this time could triple easily ..


Aclaris Therapeutics (ACRS)

Market Cap: $43 M
Cash: $115 M or enough untill end 2021 EXCLUDING Upfront payments from Out-licensing and royalties
Price: $1.08

Book Value: $3.30
Cash per Share: $2.79


Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)...
September 16, 2019
https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-101-45-topical-solution-meets-primary-and-0

“There are no FDA approved prescription treatments for common warts and we are excited by these data and look forward to the results of the second pivotal Phase 3 trial, THWART-1 (WART-301),” said Dr. Neal Walker, President and CEO of Aclaris.
Common warts, also called verruca vulgaris, are skin growths caused by a virus infecting the top layer of the skin. They affect an estimated 22 million Americans each year with a higher incidence in children than adults.



Morgan Stanley reports 5% passive stake in Aclaris Therapeutics...08/29,2019
https://thefly.com/landingPageNews.php?id=2956902


Aclaris Therapeutics Announces New Strategic Direction
https://investor.aclaristx.com/news...herapeutics-announces-new-strategic-direction


This new strategic direction includes the following actions:

Actively Seeking a Commercialization Partner for RHOFADE® (oxymetazoline hydrochloride) cream, 1%

Aclaris will also seek strategic partners for ESKATA® (hydrogen peroxide) topical solution, 40% (w/w)


Aclaris is actively seeking a strategic partner to commercialize its drug candidate A-101 45% Topical Solution, an investigational compound being developed as a potential treatment for verruca vulgaris (common warts). The Company’s two ongoing Phase 3 pivotal clinical trials, THWART-1 and THWART-2, in which A-101 45% Topical Solution is being evaluated as a potential treatment for common warts, are progressing as planned. Aclaris has completed enrollment of more than 1,000 patients across these two trials, and data from both trials are expected in the second half of 2019.

Aclaris is actively seeking a development and commercialization partner for its drug candidates, ATI-501 (oral) and ATI-502 (topical), which are investigational Janus Kinase (JAK) 1/3 inhibitor compounds for the potential treatment of alopecia.


ACRS aquired a attractive drug from Allergan last year paid $65 m upfront alone for this drug which they now looking to outlicense .

https://www.globenewswire.com/news-...orldwide-Rights-to-RHOFADE-from-Allergan.html


Pipeline
https://www.aclaristx.com/pipeline/


Largest Shareholders:

Deerfield Management Company LP...5 893 416
Franklin Advisers, Inc....3 953 203
BlackRock Fund Advisors ...2 359 223
Broadfin Capital LLC...2 280 260
D. E. Shaw & Co. LP....2 049 462
Sofinnova Ventures, Inc.....1 911 573
Vivo Capital LLC ....1 647 214
Fidelity Management & Research Co...1 562 190
Polar Capital LLP...1 443 920
The Vanguard Group, Inc...1 142 022










 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post